Literature DB >> 18923384

An in vitro model of light chain deposition disease.

John Keeling1, Guillermo A Herrera.   

Abstract

Nodular glomerulosclerosis results from increased deposition of extracellular matrix proteins and monotypic light chains. The inability of mesangial cells to degrade abnormal levels of tenascin-C--along with the increased expression of some growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta)--is crucial to the pathogenesis of light chain deposition disease (LCDD). In order to study the molecular processes contributing to LCDD, we grew mesangial cells in three-dimensional matrices and incubated the cells with free light chains purified from the urine of patients with biopsy-proven LCDD, immunoglobulin-associated amyloid deposits, or myeloma cast nephropathy. Light chains of the latter two cohorts served as controls. Mesangial cells incubated with light chains from patients with LCDD show a significant increase in tenascin-C expression, centrally located within newly formed nodules, along with increased expression of PDGF and TGF-betas, compared to mesangial cells incubated with control light chains. There was less extracellular MMP-7 even though its intracellular expression is markedly increased compared to the control. Addition of active MMP-7 degraded this excess tenascin-C in vitro, a process that could be prevented by an exogenous MMP inhibitor. Our in vitro model recapitulates in vivo findings in patients with LCDD, thus allowing definition of the sequential pathologic processes associated with glomerulopathic light chain interactions with mesangial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923384     DOI: 10.1038/ki.2008.504

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics.

Authors:  Ying Ann Chiao; Rogelio Zamilpa; Elizabeth F Lopez; Qiuxia Dai; Gladys P Escobar; Kevin Hakala; Susan T Weintraub; Merry L Lindsey
Journal:  J Proteome Res       Date:  2010-05-07       Impact factor: 4.466

2.  Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.

Authors:  Lorenzo Cavagna; Vincenzo Sepe; Francesca Bobbio-Pallavicini; Filippo Mangione; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Int Urol Nephrol       Date:  2010-06-18       Impact factor: 2.370

3.  Glomerulopathic Light Chain-Mesangial Cell Interactions: Sortilin-Related Receptor (SORL1) and Signaling.

Authors:  Guillermo A Herrera; Luis Del Pozo-Yauner; Jiamin Teng; Chun Zeng; Xinggui Shen; Takahito Moriyama; Veronica Ramirez Alcantara; Bing Liu; Elba A Turbat-Herrera
Journal:  Kidney Int Rep       Date:  2021-03-13

4.  Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.

Authors:  Helen P McWilliams-Koeppen; James S Foster; Nicole Hackenbrack; Marina Ramirez-Alvarado; Dallas Donohoe; Angela Williams; Sallie Macy; Craig Wooliver; Dale Wortham; Jennifer Morrell-Falvey; Carmen M Foster; Stephen J Kennel; Jonathan S Wall
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

5.  Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease.

Authors:  Toshiharu Ueno; Koichi Kikuchi; Ryo Hazue; Koki Mise; Keiichi Sumida; Noriko Hayami; Tatsuya Suwabe; Junichi Hoshino; Naoki Sawa; Kenji Arizono; Shigeko Hara; Kenmei Takaichi; Takeshi Fujii; Kenichi Ohashi; Yoshifumi Ubara
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

Review 6.  The pathogenesis of renal injury and treatment in light chain deposition disease.

Authors:  Qi Wang; Fang Jiang; Gaosi Xu
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531

Review 7.  Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management.

Authors:  Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela V Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.